Organon (OGN) Reports Earnings Tomorrow: What To Expect

Pharmaceutical company Organon (NYSE:OGN) will be announcing earnings results this Monday before market hours. Here’s what you need to know.

Organon beat analysts’ revenue expectations by 2.8% last quarter, reporting revenues of $1.59 billion, flat year on year. It was a strong quarter for the company, with an impressive beat of analysts’ revenue estimates and a beat of analysts’ EPS estimates.

Is Organon a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, analysts are expecting Organon’s revenue to be flat year on year at $1.57 billion, slowing from the 4.1% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.93 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Organon has missed Wall Street’s revenue estimates twice over the last two years.

Looking at Organon’s peers in the branded pharmaceuticals segment, some have already reported their Q3 results, giving us a hint as to what we can expect. Eli Lilly delivered year-on-year revenue growth of 53.9%, beating analysts’ expectations by 9.6%, and Collegium Pharmaceutical reported revenues up 31.4%, topping estimates by 10.7%. Eli Lilly traded up 6% following the results while Collegium Pharmaceutical was also up 18%.

Read our full analysis of Eli Lilly’s results here and Collegium Pharmaceutical’s results here.

There has been positive sentiment among investors in the branded pharmaceuticals segment, with share prices up 3.9% on average over the last month. Organon is down 29.4% during the same time and is heading into earnings with an average analyst price target of $10.83 (compared to the current share price of $6.78).

P.S. STOP buying the AI stocks everyone’s talking about. The real money? It’s in the profitable pick nobody’s watching yet. We’ve identified an AI profit machine that’s flying under Wall Street’s radar—for now. We can’t keep this research public forever—grab your FREE copy before we pull it offline. GO HERE NOW.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.